(Q48170019)

9 February 2018

title

Response to interferon in multiple sclerosis is related to lipid-specific oligoclonal IgM bands (English)

1 reference

9 February 2018

0 references

2

1 reference

9 February 2018

María Simó-Castelló

5

1 reference

9 February 2018

author name string

I Bosca

1

1 reference

9 February 2018

F Coret

3

1 reference

9 February 2018

M J Magraner

4

1 reference

9 February 2018

J C Alvarez-Cermeño

6

1 reference

9 February 2018

B Casanova

7

1 reference

9 February 2018

publication date

10 June 2010

1 reference

9 February 2018

Multiple Sclerosis Journal

published in

1 reference

9 February 2018

volume

16

1 reference

9 February 2018

issue

7

1 reference

9 February 2018

page(s)

810-815

1 reference

9 February 2018

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458510371961

Identifying and treating patients with suboptimal responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510371961

Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510371961

Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510371961

Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510371961

Multiple sclerosis patients with anti-lipid oligoclonal IgM show early favourable response to immunomodulatory treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510371961

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510371961

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510371961

A sensitive and reproducible method for the detection of oligoclonal IgM bands

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510371961

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510371961

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510371961

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510371961

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510371961

Predicting beta-interferon failure in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510371961

21 January 2018

Identifiers

DOI

10.1177/1352458510371961

1 reference

9 February 2018

1 reference

9 February 2018